Skip to main
GEHC

GEHC Stock Forecast & Price Target

GEHC Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 38%
Sell 0%
Strong Sell 8%

Bulls say

GE HealthCare Techs is expected to experience organic revenue growth of 3.5% in the next year due to its leading market share and diverse sales channels in the medical technology industry. Its strong backlog growth with a 2-quarter lag suggests efficient conversion into organic revenue, and its correlation with orders and book-to-bill ratios provides reliable metrics for near-term visibility. While there are risks such as increasing competition and trade dynamics, potential upside factors include reduced competition, rapid integration of recent mergers and acquisitions, and new product growth.

Bears say

GE HealthCare Techs is facing challenges due to a slower turnaround time in converting its backlog into revenue, which reflects delays in organic revenue recognition for products such as Ultrasound units, handheld devices, and Patient Care Solutions due to supply chain-related issues. Additionally, the company's new product launches and increased competition in certain sub-markets are key factors that could impact its future performance. Furthermore, the recent approval of a generic version of its core product Omnipaque may also lead to potential market share loss and decrease its revenue in the Pharmaceutical Diagnostics segment.

GEHC has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 38% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of GE HealthCare Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GE HealthCare Technologies Inc (GEHC) Forecast

Analysts have given GEHC a Buy based on their latest research and market trends.

According to 13 analysts, GEHC has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $82.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $82.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GE HealthCare Technologies Inc (GEHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.